Organ-specific differences in the epidemiology of cytomegalovirus infections in high-risk (cytomegalovirus donor seropositive, recipient seronegative) solid organ transplant recipients with prolonged follow-up: A 10-year experience.

Cytomegalovirus (CMV) causes significant morbidity in CMV donor seropositive/recipient seronegative (D+R-) solid organ transplant recipients, but organ-specific differences in CMV epidemiology and the utility of laboratory surveillance after prophylaxis (SAP) are not well characterized. We performed a single-center retrospective study of 540 CMV D+R- heart (n = 145), kidney (n = 216), or liver recipients (n = 179) who received 6 months of CMV prophylaxis followed by SAP for 12 weeks and were followed for at least 24 months after transplant. The cumulative incidence of clinically significant CMV infection (csCMVi) was higher in heart and liver recipients than in kidney recipients (66%, 65%, and 48%, respectively; P < .001). The first csCMVi episode after prophylaxis completion occurred significantly later in heart recipients (median 97 days after prophylaxis completion; interquartile range [IQR], 59-179 days) compared with kidney (median 54 days; IQR, 37-116 days; P = .004) and liver recipients (median 46 days; IQR, 32-63 days; P < .001). Of 75 heart recipients with csCMVi, 41 (55%) did not develop csCMVi until after the 12-week SAP period. Heart recipients had delayed csCMVi onset, and prolonged surveillance may be required for SAP to meaningfully reduce CMV disease risk. Strategies that promote durable CMV immune control are needed, and studies evaluating these approaches should prioritize CMV D+R- heart recipients.